Randomized, open-label, comparative trial to evaluate the effects on ovarian function of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drospirenone (DRSP) and 30 microg ethinyl estradiol (EE)

Trial Profile

Randomized, open-label, comparative trial to evaluate the effects on ovarian function of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drospirenone (DRSP) and 30 microg ethinyl estradiol (EE)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs Drospirenone/ethinylestradiol; Estradiol/nomegestrol
  • Indications Pregnancy
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Aug 2008 Actual end date changed from Apr 2008 to Jan 2008 as reported by ClinicalTrials.gov.
    • 24 Jan 2008 The expected completion date for this trial is now 1 Feb 2008.
    • 22 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top